Literature DB >> 26293887

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

Livio Garattini1, Francesca Ghislandi2, Milene Rangel Da Costa2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26293887     DOI： 10.1007/s40273-015-0322-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

Review 1.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

2.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

3.  A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.

Authors:  Mark Nuijten; Thomas Mittendorf
Journal:  Clin Ther       Date:  2010-04       Impact factor: 3.393

4.  Budget impact analysis in economic evaluation: a proposal for a clearer definition.

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2011-12

5.  In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary.

Authors:  Michael Hutchinson
Journal:  Mult Scler       Date:  2013-01       Impact factor: 6.312

6.  Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.

Authors:  Carole Dembek; Leigh Ann White; Jayson Quach; Andrea Szkurhan; Nazia Rashid; M R Blasco
Journal:  Eur J Health Econ       Date:  2013-04-25

Review 7.  Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

Authors:  Shien Guo; Christopher Pelligra; Catherine Saint-Laurent Thibault; Luis Hernandez; Anuraag Kansal
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 8.  Cost-effectiveness of disease-modifying therapies in multiple sclerosis.

Authors:  Ali Manouchehrinia; Cris S Constantinescu
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

9.  Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.

Authors:  Carlo Lazzaro; Cosetta Bianchi; Lucia Peracino; Paola Zacchetti; Antonio Uccelli
Journal:  Neurol Sci       Date:  2009-01-24       Impact factor: 3.307

Review 10.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474
View more
  2 in total

1.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

2.  The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.

Authors:  Isabela Maia Diniz; Augusto Afonso Guerra; Livia Lovato Pires de Lemos; Kathiaja M Souza; Brian Godman; Marion Bennie; Björn Wettermark; Francisco de Assis Acurcio; Juliana Alvares; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia; Vânia Eloisa de Araújo
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.